8-KEarnings & ResultsLeadership ChangesRegulation FD+1

CENTENE CORP 8-K Report, Financial Results (Jul 28, 2026)

Filed July 28, 2026For Securities:CNC

Summary

Centene Corporation (CNC) filed an 8-K on July 28, 2026, primarily to disclose its financial results for the second quarter ended June 30, 2026, via a press release (Exhibit 99.1). While the specific financial details are not within this excerpt, the filing indicates that an earnings announcement has been made. Additionally, the company announced a change in its Board of Directors. Director Kenneth Burdick resigned from the Board and the Quality and Compliance Committee, effective July 28, 2026. His resignation was stated to be amicable and not due to any disputes. Following Mr. Burdick's resignation, Centene elected Paul Diaz to the Board, effective July 28, 2026, with his term extending to the 2027 annual meeting. Mr. Diaz brings extensive experience in the healthcare sector, having held leadership positions at Kindred Healthcare, Myriad Genetics, and currently serves as a Managing Partner at Cressey & Company. He has been appointed to serve on the Audit Committee and the Quality and Compliance Committee, adding valuable expertise to the company's governance.

Key Highlights

  • 1Centene Corporation released its second quarter 2026 financial results on July 28, 2026.
  • 2Director Kenneth Burdick resigned from the Board of Directors and the Quality and Compliance Committee, effective July 28, 2026.
  • 3The resignation of Kenneth Burdick was not due to any disagreements with the Company.
  • 4Paul Diaz was elected to the Board of Directors, effective July 28, 2026, filling the vacancy left by Mr. Burdick.
  • 5Paul Diaz brings significant experience from leadership roles at Kindred Healthcare, Myriad Genetics, and Cressey & Company.
  • 6Mr. Diaz has been appointed to the Audit Committee and the Quality and Compliance Committee.
  • 7Mr. Diaz's election to the Board is in line with the Company's standard non-employee director compensation program.

Frequently Asked Questions

The 8-K filing on July 28, 2026, primarily serves to announce Centene Corporation's financial results for the second quarter ended June 30, 2026, via an accompanying press release. Specific financial metrics like revenue, earnings per share, or guidance are detailed in that press release, which is referenced as Exhibit 99.1. Investors should refer to the press release for detailed financial performance.

Kenneth Burdick resigned from Centene's Board of Directors and the Quality and Compliance Committee, effective July 28, 2026. The filing explicitly states that his resignation was not a result of any dispute or disagreement with the Company or its Board regarding operations, policies, or practices.

Paul Diaz has been elected to Centene's Board of Directors, effective July 28, 2026. He has a substantial background in the healthcare industry, including serving as President and CEO of Kindred Healthcare, and Director, President, and CEO of Myriad Genetics. He is currently a Managing Partner at Cressey & Company, a healthcare-focused private equity firm.

Upon his election to the Board, Paul Diaz has been appointed as a member of both the Audit Committee and the Quality and Compliance Committee. This placement indicates the Board's intention to leverage his expertise in financial oversight and operational quality.